CD19/CD22-Dual-STAR-T cell therapy (Hebei Yanda Ludaopei Hospital)

N/A

Report date: 2024/11/07 11:37:13

Base Information

Drug NameCD19/CD22-Dual-STAR-T cell therapy (Hebei Yanda Ludaopei Hospital)
Drug Alias NameN/A
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy
Mechanisms of ActionT lymphocyte replacementsAnti-CD19Anti-CD22
TargetsB-lymphocyte antigen CD19CD22
Therapy Area/IndicationsLeukemia, B-Cell
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusDiscontinued (Phase 1 Clinical)
Highest Status in ChinaDiscontinued
Originator CompaniesHebei Yanda Ludaopei Hospital
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesHebei Yanda Ludaopei Hospital
Active IndicationsN/A
Inactive IndicationsLeukemia, B-Cell

Other Information

ATC CodeN/A
Related LinksN/A